ClinicalTrials.gg
Status unknownNCT02527811Updated Jan 17, 2018

Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

A Phase 4 interventional study of Ulinastatin in Congenital Heart Diseases, sponsored by Techpool Bio-Pharma Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 30 Days to 4 Years. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by Techpool Bio-Pharma Co., Ltd. (part of Shanghai Pharmaceuticals Holding Co., Ltd) · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
30 Days to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies in Heart Defects, Congenital with a site in China — 27 open to participants now, 30 under way, none of them phase 3. Heart Defects, Congenital · China.

Planned enrollment
10th of 41
450 · median 160
Started
2015
with 3 others
Phase 4
2 of 79
1 open now
Registered
15th of 79
by date

Among the 79 studies in Heart Defects, Congenital with a site in China, this one is the 10th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2015, is one of 2 in phase 4, and was the 15th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

27 of the 79 studies in Heart Defects, Congenital with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: 30 Days to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Heart Defects, Congenital with a site in China, or all of them as a file.
02

Study summary

  1. Explore the efficacy of Ulinastatin use in improving post-operative pulmonary insufficiency and safety in pediatric patients undergoing scheduled CPB open heart surgery to treat Complex Congenital Heart Disease
  2. Explore the efficacy of Ulinastatin use in improving intraoperative hemodynamic instability as well as other post-operative organ recuperation and its impact on hospital stay \& cost
Read the detailed description

Pediatric patients diagnosed with Complex Congenital Heart Disease ready to accept scheduled open-heart surgery under cardiopulmonary bypass (CPB).

This study uses randomized (centralized randomization) \& controlled design with open label. Eligible subjects will be randomized to receive either study drug (Ulinastatin) or conventional treatment.

03

Conditions studied

  • Congenital Heart Diseases

Keywords

  • ulinastatin
  • CPB
  • pediatric
04

Who can participate

Ages eligible
30 Days to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children diagnosed with Complex Congenital Heart Disease .
  2. Hospitalized children, both gender, aged ≥ 30 days to ≤ 4 years.
  3. Preoperative assessment meet with surgical condition.
  4. Without signs of Liver, Kidney, and Coagulatory dysfunction.
  5. Written form has been signed by the Legal Guardian.

Exclusion criteria

Exclusion Criteria:

  1. Patients will accept minimally invasive surgery or palliative surgery, as well as Major Aortopulmonary Collateral Arteries (MAPCAs);
  2. Its decided that subject needs to undergo second surgery in a short period of time, or underwent other major surgery.
  3. Subjects with known to study medication (Ulinastatin for Injection) or patients with highly allergic history.
  4. Though meeting the study inclusion criteria, the Legal Guardian reject to sign on . Or at the discretion of study investigator/coinvestigator that the subjects is not appropriate to be included in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    ulinastatin group

    the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.

    Drug: Ulinastatin

  • No intervention
    control group

    patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.

Interventions

  • Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative

    Also known as: UTI, urinary trypsin inhibitor, bikunin

06

What researchers measure

Primary outcomes

  1. Dynamic changes of arterial oxygen tension / inspired oxygen fraction (PaO2/FiO2) ratio

    Dynamic changes of PaO2/FiO2 ratio will be observed in every 4 hours interval during post-operative ICU stay period

    Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days

Secondary outcomes

  1. The time of the PaO2/ FiO2 Ratio ≥300 post surgery

    Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days

  2. The proportion of the PaO2/ FiO2 Ratio ≥300 post surgery

    Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days

  3. Monitoring arterial hydrogen ion concentration

    Time frame: Participants will be followed for the duration of ICU, an expected average of 5 days

  4. Monitoring record of mean blood pressure

    Time frame: Intraoperative and Postoperative,an expected average of 6 days

  5. Monitoring record of central venous pressure

    Time frame: Intraoperative and Postoperative,an expected average of 6 days

  6. Analysis proinflammatory cytokines Interleukin 1

    Time frame: Preoperative and Postoperative on day1 ,day3 and day5

07

Study locations

5 sites
  • General Hospital of Guangzhou Millitary Command
    Guangzhou, Guangdong 510010, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510623, China
  • Nanjing Children's Hospital
    Nanjing, Jiangsu 210000, China
  • Shanghai Children's Medical Center
    Shanghai, 200127, China
  • Children's Hospital of Fudan University
    Shanghai, 201102, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jun 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2014
First posted
Aug 19, 2015
Start
Apr 2015
Primary completionEst.
Jun 2018
CompletionEst.
Dec 2018
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02527811
Collaborators
Shanghai Children's Medical Center, Guangzhou Women and Children's Medical Center, Guangzhou General Hospital of Guangzhou Military Command, Nanjing Children's Hospital, Children's Hospital of Fudan University
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Apr 2015
Primary completion
Jun 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jan 17, 2018

Study contacts

Wei Wang, MD
study chair · Shanghai Children's Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urinastatin

Start the discussion